PSA levels guide metastatic prostate cancer treatment decisions

A new study suggests that prostate-specific antigen (PSA) levels can help predict the prognosis of metastatic prostate cancer patients, potentially guiding treatment decisions. A PSA level of 0.2 ng/mL or higher indicates a poor outcome. The IRONMAN study found that patients with a PSA level of 0.2 ng/mL or greater after 6-12 months of treatment had significantly worse overall and progression-free survival. Conversely, a PSA under 0.2 ng/mL predicted a better prognosis. Researchers are now conducting clinical trials to assess treatment escalation for patients with elevated PSA and de-escalation for those with low PSA levels, based on these findings. The study was presented at the American Society of Clinical Oncology annual meeting.